Fundz

Watching Viking Therapeutics, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Viking Therapeutics, Inc.

Filed: Jul 29, 2026CIK: 0001607678
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Viking Therapeutics, Inc. reported its Q2 2026 financial results on July 29, 2026, disclosing revenue, net income, and operational updates including pipeline product developments and forward guidance.

Key Takeaways

Company disclosed Q2 2026 financial performance including revenue figures and net income results

Filing includes updates on pipeline product developments and clinical progress

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 29, 2026
Item2.02
CategoryFinancial Results
CIK0001607678
Accession #0001607678
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings

Viking Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.